Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 12000743 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Wang Z, Frederick J, Garabedian MJ (2002) Deciphering the phosphorylation "code" of the glucocorticoid receptor in vivo. J Biol Chem 277, 26573-80 12000743
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S203-p - GR (human)
Orthologous residues
GR (human): S203‑p, GR iso2 (human): S203‑p, GR (mouse): S212‑p, GR (rat): S224‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  bone cancer, lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary), liver, lymph node, prostate, thyroid, U2OS (bone cell) [GR (human)]
 Cellular systems studied:  cell lines, tissue
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
dexamethasone increase
RU-486 increase
prednisolone increase
fluocinolone increase
ZK299 no change compared to control
RU-486 dexamethasone no effect upon treatment-induced increase
ZK299 dexamethasone no effect upon treatment-induced increase

S211-p - GR (human)
Orthologous residues
GR (human): S211‑p, GR iso2 (human): S211‑p, GR (mouse): S220‑p, GR (rat): S232‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  bone cancer, lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary), liver, lymph node, prostate, thyroid, U2OS (bone cell) [GR (human)]
 Cellular systems studied:  cell lines, tissue
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
dexamethasone increase
RU-486 increase
prednisolone increase
fluocinolone increase
ZK299 no change compared to control
RU-486 dexamethasone inhibit treatment-induced increase
ZK299 dexamethasone inhibit treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.